Skip to main content
Device/Product name
Active Ingredient
Date of decision
Submission type
New biological entity
ATC codes
Approved for provisional registration
What was the decision based on
The decision was based on quality (chemistry and manufacturing), nonclinical (pharmacology and toxicology), clinical (pharmacology, safety and efficacy) and risk management plan information submitted by the sponsor. The benefit-risk profile of Jemperli was considered favourable for the therapeutic use approved.
What steps were involved in the decision process

Registration timeline

The following table summarises the key steps and dates for this application.

Description Date
Determination (Provisional) 15 September 2020
Submission dossier accepted and first round evaluation commenced 1 February 2021
First round evaluation completed 30 June 2021
Sponsor provides responses on questions raised in first round evaluation 31 August 2021
Second round evaluation completed 6 October 2021
Delegate's overall benefit-risk assessment 6 January 2022
Sponsor's pre-Advisory Committee response Not applicable
Advisory Committee meeting Not applicable
Registration decision (Outcome) 15 February 2022
Completion of administrative activities and registration on ARTG 17 February 2022
Number of working days from submission dossier acceptance to registration decision* 208

*Statutory timeframe for standard applications is 255 working days

Date of entry onto ARTG
Original publication date
Black triangle scheme
As a provisionally registered product, this medicine will remain in the Black Triangle Scheme for the duration of its provisional registration
Dose forms
Solution for infusion (concentrate)
500 mg/10 mL
Other ingredients
Sodium citrate dihydrate, citric acid monohydrate, arginine hydrochloride, sodium chloride, polysorbate 80 and water for injection
Pack sizes
Routes of administration

The recommended dose as monotherapy is 500 mg dostarlimab administered as an intravenous infusion over 30 minutes every 3 weeks for 4 doses followed by 1,000 mg every 6 weeks for all cycles thereafter.

For further information refer to the Product Information.

Pregnancy category
DDrugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.The use of any medicine during pregnancy requires careful consideration of both risks and benefits by the treating health professional. This must not be used as the sole basis of decision making in the use of medicines during pregnancy. The TGA does not provide advice on the use of medicines in pregnancy for specific cases. More information is available from obstetric drug information services in your State or Territory.
What was approved

Jemperli (dostarlimab) was approved for the following therapeutic use:

Jemperli is indicated as monotherapy for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dMMR) endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.

This medicine and indication have provisional approval, based on objective response rate and duration of response in a single-arm trial. Full registration for this indication depends on verification and description of clinical benefit in confirmatory trials.

What is this medicine and how does it work
Dostarlimab is an anti programmed cell death protein 1 (PD 1) immunoglobulin G4 (IgG4) humanised monoclonal antibody (mAb), derived from a stable Chinese hamster ovary (CHO) cell line.Binding of the PD 1 ligands, PD L1 and PD L2, to the PD 1 receptor found on T cells inhibits T cell proliferation and cytokine production. Upregulation of PD 1 ligands occur in some tumours and signalling through this pathway can contribute to inhibition of active T cell immune surveillance of tumours. Dostarlimab is a humanised mAb of IgG4 isotype that binds to PD 1, resulting in inhibition of binding to PD L1 and PD L2, releasing inhibition of PD 1 pathway mediated immune response, including the antitumour immune response. In syngeneic mouse tumour models, blocking PD 1 activity resulted in decreased tumour growth.
What post-market commitments will the sponsor undertake
  • Jemperli (dostarlimab) is to be included in the Black Triangle Scheme. The [Product Information] PI and [Consumer Medicines Information] CMI for Jemperli must include the black triangle symbol and mandatory accompanying text for the products entire period of provisional registration.
  • The Jemperli [European Union] EU-risk management plan (RMP) (version 1.1, dated 12 April 2021, data lock point 1 March 2020), with Australian specific annex (version 3.0 dated October 2021), included with Submission PM 2020 06455 1 4, and any subsequent revisions, as agreed with the TGA will be implemented in Australia.

    An obligatory component of risk management plans is routine pharmacovigilance. Routine pharmacovigilance includes the submission of periodic safety update reports (PSURs).

    Unless agreed separately between the supplier who is the recipient of the approval and the TGA, the first report must be submitted to TGA no later than 15 calendar months after the date of the approval letter. The subsequent reports must be submitted no less frequently than annually from the date of the first submitted report until the period covered by such reports is not less than three years from the date of the approval letter, or the entire period of provisional registration, whichever is longer.

    The reports are to at least meet the requirements for PSURs as described in the European Medicines Agency's guideline on Good Pharmacovigilance Practices (GVP) Module VII-periodic safety update report ([revision] 1), Part VII.B structures and processes. Note that submission of a PSUR does not constitute an application to vary the registration. Each report must have been prepared within ninety calendar days of the data lock point for that report.

  • Laboratory testing and compliance with Certified Product Details (CPD)
    • All batches of Jemperli dostarlimab 500 mg solution for infusion 10 mL vial supplied in Australia must comply with the product details and specifications approved during evaluation and detailed in Certified Product Details (CPD).
    • When requested by the TGA, the sponsor should be prepared to provide product samples, specified reference materials and documentary evidence to enable the TGA to conduct laboratory testing on the product. Outcomes of laboratory testing are published biannually in the TGA database of laboratory testing results and periodically in testing reports on the TGA website.
  • Certified Product Details

    The Certified Product Details (CPD), as described in Guidance 7: Certified Product Details of the Australian Regulatory Guidelines for Prescription Medicines (ARGPM), in [portable document format] PDF format, for the above products should be provided upon registration of these therapeutic goods. In addition, an updated CPD should be provided when changes to finished product specifications and test methods are approved in a category 3 application or notified through a self-assessable change.

    The CPD should be emailed as a single PDF document.

  • Confirmatory trial data (as identified in the sponsor's plan to submit comprehensive clinical data on the safety and efficacy of the medicine before the end of the 6 years that would start on the day that registration would commence) must be provided.

    Specifically, the sponsor must conduct studies as described in the clinical study plan in version 3.0 (dated October 2021) of the Australia specific annex. The following study reports should be submitted to TGA:

    • Study 4010 01 001 [the GARNET trial] by date 14 January 2028, and
    • Study 4010 03 001 [the RUBY trial] by date 14 January 2028

    Further guidance for sponsors is available on the TGA website.

  • For all injectable products the Product Information must be included with the product as a package insert.

Help us improve the Therapeutic Goods Administration site